Provided by Tiger Trade Technology Pte. Ltd.

ADMA Biologics

9.55
-0.2900-2.95%
Post-market: 9.46-0.0900-0.94%19:30 EDT
Volume:1.96M
Turnover:18.90M
Market Cap:2.14B
PE:13.64
High:9.91
Open:9.80
Low:9.54
Close:9.84
52wk High:20.46
52wk Low:7.21
Shares:223.98M
Float Shares:210.51M
Volume Ratio:1.06
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7004
EPS(LYR):0.6000
ROE:41.90%
ROA:21.78%
PB:5.24
PE(LYR):15.92

Loading ...

A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations

Simply Wall St.
·
Apr 09

Assessing ADMA Biologics (ADMA) Valuation After Rebuttal To Short Seller Allegations

Simply Wall St.
·
Mar 31

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Energy shares, miners, Sysco

Reuters
·
Mar 30

BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Adma Biologics call volume above normal and directionally bullish

TIPRANKS
·
Mar 27

Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday

Benzinga
·
Mar 27

BUZZ-ADMA Biologics rises after rejecting short-seller's claims

Reuters
·
Mar 27

ADMA Biologics Issues Rebuttal to Short-Seller Allegations

TIPRANKS
·
Mar 27

Adma Biologics responds to short seller report by Culper Research

TIPRANKS
·
Mar 27

ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026

Reuters
·
Mar 27

ADMA Biologics Inc: Short Report Misrepresents and Conflates Asceniv's Utility and Competitive Positioning in Ivig Market

THOMSON REUTERS
·
Mar 27

ADMA Biologics : Refutes Key Allegations to Alleviate Confusion in Marketplace Concerning Company's Business Practices and Operations

THOMSON REUTERS
·
Mar 27

ADMA Biologics : as a Late Line Therapy for Patients Who Have Failed Standard Ig, Asceniv Is in a Different Category and Commands Premium Pricing

THOMSON REUTERS
·
Mar 27

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

GlobeNewswire
·
Mar 27

Why Are Shares Of ADMA Biologics Falling Today?

Benzinga
·
Mar 27

ADMA Biologics Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
Mar 26

Adma Biologics says Culper report contains ‘inaccurate statements’

TIPRANKS
·
Mar 26